MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis. It also provides the Miriad RVF toolkit, which facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
Visit company website
5 years, 5 months ago
MedMira Inc is currently in a long term downtrend where the price is trading 44.7% below its 200 day moving average.
From a valuation standpoint, the stock is 93.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 67.7.
MedMira Inc's total revenue rose by 1587.0% to $2M since the same quarter in the previous year.
Its net income has increased by 216.4% to $715K since the same quarter in the previous year.
Finally, its free cash flow grew by 11.8% to $-363K since the same quarter in the previous year.
Based on the above factors, MedMira Inc gets an overall score of 4/5.